<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.111020</article-id><article-id pub-id-type="publisher-id">ACM-39796</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210100000_13119017.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  诱导性多能干细胞在多发性硬化中的研究现状
  Research Status of Induced Pluripotent Stem Cells in Multiple Sclerosis
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>郑</surname><given-names>钦日</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>null</addr-line></aff><aff id="aff2"><label>1</label><addr-line>马来西亚博特拉大学生物科学研究所益生菌与治疗研究实验室，沙登，雪兰莪，马来西亚</addr-line></aff><pub-date pub-type="epub"><day>07</day><month>01</month><year>2021</year></pub-date><volume>11</volume><issue>01</issue><fpage>138</fpage><lpage>142</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    多发性硬化(multiple sclerosis, MS)是一种常见的中枢神经系统炎性脱髓鞘疾病，好发于中青年，是成人神经性致残的主要原因。因其有较高的发病率、慢性病程和青壮年易患而备受关注。目前MS尚无有效的根治疗法，临床上仍以疾病修正治疗为主。因此探索新的治疗方法尤为重要。诱导性多能干细胞(induced pluripotent stem cells, iPSCs)具有干细胞的分化全能性，不仅成功避开了胚胎干细胞的伦理问题，同时也解决了干细胞来源受限的问题，有望成为MS的良好治疗方式。
    Multiple sclerosis (MS) is a common inflammatory demyelinating disease of the central nervous system, which occurs in young and middle-aged people and is the main cause of neurological disability in adults. Because of its high morbidity, chronic course, and susceptibility to young adults, it has attracted much attention. At present, there is no effective root therapy for MS, and the disease correction therapy is still the main clinical practice. Therefore, it is particularly important to explore new treatment methods. Induced pluripotent stem cells (iPSCs) have stem cell differentiation totipotency, which not only successfully avoids the ethical problems of embryonic stem cells, but also solves the problem of limited stem cell sources. It is expected to become a good treatment for MS. 
  
 
</p></abstract><kwd-group><kwd>多发性硬化，诱导性多能干细胞，干细胞疗法, Multiple Sclerosis</kwd><kwd> Induced Pluripotent Stem Cells</kwd><kwd> Stem Cell Therapy</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>多发性硬化(multiple sclerosis, MS)是一种常见的中枢神经系统炎性脱髓鞘疾病，好发于中青年，是成人神经性致残的主要原因。因其有较高的发病率、慢性病程和青壮年易患而备受关注。目前MS尚无有效的根治疗法，临床上仍以疾病修正治疗为主。因此探索新的治疗方法尤为重要。诱导性多能干细胞(induced pluripotent stem cells, iPSCs)具有干细胞的分化全能性，不仅成功避开了胚胎干细胞的伦理问题，同时也解决了干细胞来源受限的问题，有望成为MS的良好治疗方式。</p></sec><sec id="s2"><title>关键词</title><p>多发性硬化，诱导性多能干细胞，干细胞疗法</p></sec><sec id="s3"><title>Research Status of Induced Pluripotent Stem Cells in Multiple Sclerosis</title><p>Qinri Zheng</p><p>Probiotics and Therapeutic Research Laboratory, Institute of Biological Sciences, Putra University, Malaysia, Serdang, Selangor, Malaysia</p><p><img src="//html.hanspub.org/file/20-1571851x5_hanspub.png" /></p><p>Received: Dec. 14<sup>th</sup>, 2020; accepted: Jan. 3<sup>rd</sup>, 2021; published: Jan. 18<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/20-1571851x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Multiple sclerosis (MS) is a common inflammatory demyelinating disease of the central nervous system, which occurs in young and middle-aged people and is the main cause of neurological disability in adults. Because of its high morbidity, chronic course, and susceptibility to young adults, it has attracted much attention. At present, there is no effective root therapy for MS, and the disease correction therapy is still the main clinical practice. Therefore, it is particularly important to explore new treatment methods. Induced pluripotent stem cells (iPSCs) have stem cell differentiation totipotency, which not only successfully avoids the ethical problems of embryonic stem cells, but also solves the problem of limited stem cell sources. It is expected to become a good treatment for MS.</p><p>Keywords:Multiple Sclerosis, Induced Pluripotent Stem Cells, Stem Cell Therapy</p><disp-formula id="hanspub.39796-formula21"><graphic xlink:href="//html.hanspub.org/file/20-1571851x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/20-1571851x8_hanspub.png" /> <img src="//html.hanspub.org/file/20-1571851x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 前言</title><p>多发性硬化症(MS)是一种常见的神经系统疾病，主要针对中枢神经系统(central nervous system, CNS)中的白质，即大脑和脊髓 [<xref ref-type="bibr" rid="hanspub.39796-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.39796-ref2">2</xref>]。MS主要影响20至40岁的患者，女性患者约是男性患者的1.5至2倍。其特征是节段性脱髓鞘、轴突损伤、神经元和少突胶质细胞丢失，导致神经功能障碍和残疾。MS仍然是年轻人致残的主要原因之一。当前的治疗方法包括复发治疗、疾病缓解治疗和症状治疗 [<xref ref-type="bibr" rid="hanspub.39796-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.39796-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.39796-ref5">5</xref>]。经批准的治疗多发性硬化症的方法要么疗效有限，要么存在严重的安全性问题。因此干细胞替代治疗为多发性硬化症提供了希望。诱导性多能干细胞(iPSC)是再生医学中新兴的细胞来源，目前也正在测试其治疗MS的能力。在将iPSC衍生的神经细胞移植到脱髓鞘的模型中后，观察到活动性和强健的髓鞘再生显著改善。在这里，我们讨论针对MS的干细胞疗法的最新进展，重点是基于iPSC的干细胞疗法。</p></sec><sec id="s6"><title>2. 诱导多能性干细胞</title><p>诱导性多能干细胞(induced pluripotent stem cell, iPSC)是通过在已分化的体细胞中表达特定的基因或特定基因产物等方式，以诱导体细胞的重编程而获得可不断自我更新且具有多向分化潜能的细胞。这些细胞有成为OPC的潜力，因此它们可能从自体来源构成一种合适的细胞治疗模式 [<xref ref-type="bibr" rid="hanspub.39796-ref6">6</xref>]。iPSP最初是由日本京都大学的山中伸弥(Shinya Yamanaka)和他的同事从小鼠胚胎和成年成纤维细胞中产生的。Yamanaka的小组使用逆转录病毒载体Octamer 3/4 (OCT3/4)、SRY-box-containing gene 2 (SOX2)、细胞质Myc蛋白(c-MYC)和krueppell样因子4 (KLF4)重新编程小鼠和人类干细胞治疗多发性硬化症。此后不久，也成功地从MS患者的细胞中产生了iPSC [<xref ref-type="bibr" rid="hanspub.39796-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.39796-ref8">8</xref>] 将衍生自iPSCs的NSC和少突胶质祖细胞(OPC)移植到EAE小鼠和其他脱髓鞘动物模型后，观察到残疾和髓鞘再生得到改善 [<xref ref-type="bibr" rid="hanspub.39796-ref9">9</xref>] [<xref ref-type="bibr" rid="hanspub.39796-ref10">10</xref>]。与其他干细胞相比，iPSC具有从患者体细胞中获得的巨大优势，从而避免了移植排斥的风险和道德上的顾虑。iPSC的突破性创新引发了全球范围内的巨大努力，以开展疾病建模，药物筛选和再生疗法。重新编程的细胞具有与胚胎干细胞(ESC)相似的形态，并且可以分化为代表所有三个胚胎生殖层的细胞类型 [<xref ref-type="bibr" rid="hanspub.39796-ref11">11</xref>]。随后从健康和患病个体产生人iPSC的成功尝试使我们更接近于临床应用。</p></sec><sec id="s7"><title>3. IPSCs可以在体外分化为少突胶质细胞系</title><p>iPSCs成功分化为少突胶质细胞系是MS治疗的基础。2010年，Tokumoto将小鼠iPSC与ESC的区分能力进行了比较。诱导后，在iPSC和ESC来源的细胞中均观察到OPC标记A2B5阳性细胞和少突胶质细胞特异性细胞表面标记O4阳性细胞 [<xref ref-type="bibr" rid="hanspub.39796-ref12">12</xref>]。表明IPSCs和胚胎干细胞相似，均有分化成少突胶质细胞的潜能。2011年，人类iPSC首次被诱导分化为少突胶质细胞 [<xref ref-type="bibr" rid="hanspub.39796-ref13">13</xref>]。健康成年人的成纤维细胞衍生的iPSC用表皮生长因子依赖性分化方案治疗，最终分化为O4 + 少突胶质细胞。复发缓解型多发性硬化症(RRMS)和原发性进行性多发性硬化症(PPMS)患者的成纤维细胞也被重新编程为iPSC，这些MS-iPSC成功地分化为具有正常核型的成熟神经元，星形胶质细胞和少突胶质细胞。MS-iPSC衍生的神经元具有电生理功能，而少突胶质细胞对髓鞘碱性蛋白(MBP)和O4呈阳性染色。这一研究结果表明，MS来源的iPSCs最终可以分化成功能神经细胞，为实现MS的个体化治疗提供了更多可行性。</p>iPSC衍生的NSC对EAE的影响<p>考虑到脑室下区和BM来源的NSC对EAE的治疗作用 [<xref ref-type="bibr" rid="hanspub.39796-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.39796-ref15">15</xref>]，有人提出iPSC来源的NSC具有类似的作用。为了测试这一点，Laterza等人。从小鼠iPSC生成NSC，然后将其鞘内移植到MOG诱导的EAE小鼠中。经NSC处理的EAE小鼠临床表现改善，脱髓鞘面积减少，脊髓轴突损伤。iPSC的治疗潜力仍在研究中，一些研究表明，大多数移植的NSC在体内没有分化为少突胶质细胞谱系，少突胶质细胞前体来源的iPSC能够改善EAE的临床和病理特征 [<xref ref-type="bibr" rid="hanspub.39796-ref16">16</xref>]。然而，治疗效果被发现主要是由于神经保护作用，而不是再髓鞘化，表明它们没有直接参与髓鞘再生。然而，iPSC衍生的NSC通过分泌特定的神经营养蛋白：白血病抑制因子，促进了内源性髓鞘形成细胞的存活和分化。NSCs介导的营养作用也改善了BBB的完整性，从而限制了CNS限制的炎症 [<xref ref-type="bibr" rid="hanspub.39796-ref9">9</xref>]。考虑到髓磷脂损害通常是由中枢神经系统炎症引起的，因此在炎性环境中发挥神经保护作用和神经营养作用使iPSC-NSCs成为治疗MS的有希望的细胞来源。此外，iPSC对选定的细胞表型的有效分化可能代表了对疾病定向治疗的巨大研究挑战。最后，最近的研究表明，由于潜在的恶性转化和免疫排斥，临床发展需要谨慎 [<xref ref-type="bibr" rid="hanspub.39796-ref17">17</xref>] [<xref ref-type="bibr" rid="hanspub.39796-ref18">18</xref>]。</p></sec><sec id="s8"><title>4. IPSP的机制</title><p>由于内源性髓鞘再灌注不足，细胞治疗在多发性硬化症治疗中正在向前发展。诱导多能干细胞的治疗效果不受细胞替代的限制。诱导多能干细胞还具有免疫抑制作用，为内源性修复机制提供营养支持。鼻咽癌移植减少T细胞浸润 [<xref ref-type="bibr" rid="hanspub.39796-ref19">19</xref>] [<xref ref-type="bibr" rid="hanspub.39796-ref20">20</xref>]。移植的NPCs分泌的LIF对内源性少突胶质细胞具有营养作用。除了细胞替代之外，诱导多能干细胞还被用于体外疾病建模，以了解疾病的潜在机制，并用于筛选改变疾病过程的药物。2011年，一名患有RRMS的35岁患者的成纤维细胞首次生成了MS患者特异性的iPSCs [<xref ref-type="bibr" rid="hanspub.39796-ref7">7</xref>]。成功地将患者来源的诱导多能干细胞分化为神经前体细胞和成熟神经元。随后，PPMS患者也产生了患者间充质干细胞 [<xref ref-type="bibr" rid="hanspub.39796-ref21">21</xref>]。在Douvaras等人的研究中，4个iPSC系被转化为NSCs和OPCs，它们携带正常的核型。移植的OPCs为颤抖小鼠提供了髓鞘形成。类似的研究应该继续进行，特别是在疾病建模的遗传负荷高的MS患者。</p>IPSP治疗MS挑战<p>MS中基于iPSC的处理仍存在一些问题。首先，iPSC生成方法仍需改进。另一个问题是移植时对初始细胞类型的偏好。OPCs具有较好的细胞替代作用，但这些细胞的抗炎和营养作用尚未得到证实。NSCs可以分化为所有的神经细胞谱系，也有抗炎和营养作用，但它们也可能分化为星形胶质细胞，因此导致MS中不必要的星形胶质细胞增生。另一个主要问题是细胞给药的途径。直接脑内或椎管内注射似乎更有效，但在临床应用中并不实用。鼻内途径也可以有效使用，是MS中使用iPSCs的一种侵入性较小的途径。然后，应该考虑使用异基因或自体诱导多能干细胞。自体诱导多能干细胞更好，但由于自身疾病因素，它们可能无效 [<xref ref-type="bibr" rid="hanspub.39796-ref21">21</xref>]。为了避免免疫原性，健康干细胞治疗多发性硬化异基因iPSC治疗需要免疫抑制治疗，可能导致多发性硬化症复发。最后诱导多能干细胞与胚胎干细胞有相似的特征，例如产生许多不同的组织类型，并且能够在培养中无限分裂。然而，诱导多能干细胞的肿瘤形成风险非常高。</p></sec><sec id="s9"><title>5. 展望</title><p>随着预期寿命的增加，神经退行性疾病的发病率将显著增加，这是一个重大的经济和社会负担。虽然目前的治疗可以减轻一些症状，但在阻止大多数神经退行性疾病的进展方面，它们通常是无效的。目前，针对MS的其他基于干细胞的新疗法还处于早期阶段，包括基于hESC、iPSC和NSC的疗法。iPSC技术开辟了前所未有的机遇为研究细胞过程导致神经退行性变的早期，和开发新的高通量药物筛选平台，可以更准确地预测治疗产品的功效。虽然细胞重新编程技术有可能彻底改变我们的方法研究和治疗各种神经疾病，但仍然存在很多问题。干细胞移植可被视为治疗多发性硬化的一个潜在来源，然而，在将干细胞治疗大规模引入临床之前，必须克服干细胞治疗研究中的方法学、伦理和临床挑战。</p></sec><sec id="s10"><title>文章引用</title><p>郑钦日. 诱导性多能干细胞在多发性硬化中的研究现状Research Status of Induced Pluripotent Stem Cells in Multiple Sclerosis[J]. 临床医学进展, 2021, 11(01): 138-142. https://doi.org/10.12677/ACM.2021.111020</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.39796-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Noseworthy, J.H., Lucchinetti, C., Rodriguez, M. and Weinshenker, B.G. (2000) Multiple Sclerosis. The New England Journal of Medicine, 343, 938-952. &lt;br&gt;https://doi.org/10.1056/NEJM200009283431307</mixed-citation></ref><ref id="hanspub.39796-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Compston, A. and Coles, A. (2008) Multiple Sclerosis. The Lancet, 372, 1502-1517.  
&lt;br&gt;https://doi.org/10.1016/S0140-6736(08)61620-7</mixed-citation></ref><ref id="hanspub.39796-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Polman, C.H., Reingold, S.C., Banwell, B., et al. (2011) Diagnostic Criteria for Multiple Sclerosis: 2010 Revisions to the McDonald Criteria. Annals of Neurology, 69, 292-302. &lt;br&gt;https://doi.org/10.1002/ana.22366</mixed-citation></ref><ref id="hanspub.39796-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Poser, C.M. and Brinar, V.V. (2001) Diagnostic Criteria for Multiple Sclerosis. Clinical Neurology and Neurosurgery, 103, 1-11. &lt;br&gt;https://doi.org/10.1016/S0303-8467(00)00125-6</mixed-citation></ref><ref id="hanspub.39796-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Polman, C.H., Reingold, S.C., Edan, G., et al. (2005) Diagnostic Criteria for Multiple Sclerosis: 2005 Revisions to the “McDonald Criteria”. Annals of Neurology, 58, 840-846. &lt;br&gt;https://doi.org/10.1002/ana.20703</mixed-citation></ref><ref id="hanspub.39796-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Almeida, S., Gascon, E., Tran, H., Chou, H.J., Gendron, T.F., et al. (2013) Modeling Key Pathological Features of Frontotemporal Dementia with C9ORF72 Repeat Expansion in iPSC-Derived Human Neurons. Acta Neuropathologica, 126, 385-399. &lt;br&gt;https://doi.org/10.1007/s00401-013-1149-y</mixed-citation></ref><ref id="hanspub.39796-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Song, B., Sun, G., Herszfeld, D., et al. (2012) Neural Differentiation of Patient Specific iPS Cells as a Novel Approach to Study the Pathophysiology of Multiple Sclerosis. Stem Cell Research, 8, 259-273.  
&lt;br&gt;https://doi.org/10.1016/j.scr.2011.12.001</mixed-citation></ref><ref id="hanspub.39796-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Douvaras, P., Wang, J., Zimmer, M., et al. (2014) Efficient Generation of Myelinating Oligodendrocytes from Primary Progressive Multiple Sclerosis Patients by Induced Pluripotent Stem Cells. Stem Cell Reports, 3, 250-259.  
&lt;br&gt;https://doi.org/10.1016/j.stemcr.2014.06.012</mixed-citation></ref><ref id="hanspub.39796-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Laterza, C., Merlini, A., De Feo, D., et al. (2013) iPSC-Derived Neural Precursors Exert a Neuroprotective Role in Immune-Mediated Demyelination via the Secretion of LIF. Nature Communications, 4, 2597.  
&lt;br&gt;https://doi.org/10.1038/ncomms3597</mixed-citation></ref><ref id="hanspub.39796-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Wang, S., Bates, J., Li, X., et al. (2013) Human iPSC-Derived Oligodendrocyte Progenitor Cells Can Myelinate and Rescue a Mouse Model of Congenital Hypomyelination. Cell Stem Cell, 12, 252-264.  
&lt;br&gt;https://doi.org/10.1016/j.stem.2012.12.002</mixed-citation></ref><ref id="hanspub.39796-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Takahashi, K. and Yamanaka, S. (2006) Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors. Cell, 126, 663-676. &lt;br&gt;https://doi.org/10.1016/j.cell.2006.07.024</mixed-citation></ref><ref id="hanspub.39796-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Tokumoto, Y., Ogawa, S., Nagamune, T. and Miyake, J. (2010) Comparison of Efficiency of Terminal Differentiation of Oligodendrocytes from Induced Pluripotent Stem Cells versus Embryonic Stem Cells in Vitro. Journal of Bioscience and Bioengineering, 109, 622-628. &lt;br&gt;https://doi.org/10.1016/j.jbiosc.2009.11.013</mixed-citation></ref><ref id="hanspub.39796-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Ogawa, S., Tokumoto, Y., Miyake, J. and Nagamune, T. (2011) Induction of Oligodendrocyte Differentiation from Adult Human Fibroblast-Derived Induced Pluripotent Stem Cells. In Vitro Cellular &amp; Developmental Biology—Animal, 47, 464-469. &lt;br&gt;https://doi.org/10.1007/s11626-011-9435-2</mixed-citation></ref><ref id="hanspub.39796-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Pluchino, S., Quattrini, A., Brambilla, E., et al. (2003) Injection of Adult Neurospheres Induces Recovery in a Chronic Model of Multiple Sclerosis. Nature, 422, 688-694. &lt;br&gt;https://doi.org/10.1038/nature01552</mixed-citation></ref><ref id="hanspub.39796-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Yang, J., Yan, Y., Ciric, B., et al. (2010) Evaluation of Bone Marrow- and Brain-Derived Neural Stem Cells in Therapy of Central Nervous System Autoimmunity. The American Journal of Pathology, 177, 1989-2001.  
&lt;br&gt;https://doi.org/10.2353/ajpath.2010.091203</mixed-citation></ref><ref id="hanspub.39796-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Sareen, D., O’Rourke, J.G., Meera, P., Muhammad, A.K., Grant, S., et al. (2013) Targeting RNA Foci in iPSC-Derived Motor Neurons from ALS Patients with a C9ORF72 Repeat Expansion. Science Translational Medicine, 5, 208ra149.  
&lt;br&gt;https://doi.org/10.1126/scitranslmed.3007529</mixed-citation></ref><ref id="hanspub.39796-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Donnelly, C.J., Zhang, P.W., Pham, J.T., Heusler, A.R., Mistry, N.A., et al. (2013) RNA Toxicity from the ALS/FTD C9ORF72 Expansion Is Mitigated by Antisense Intervention. Neuron, 80, 415-428.  
&lt;br&gt;https://doi.org/10.1016/j.neuron.2013.10.015</mixed-citation></ref><ref id="hanspub.39796-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Teuling, E., Ahmed, S., Haasdijk, E., Demmers, J., Steinmetz, M.O., Akhmanova, A., et al. (2007) Motor Neuron Disease-Associated Mutant Vesicle-Associated Membrane Protein-Associated Protein (VAP) B Recruits Wild-Type VAPs into Endoplasmic Reticulum-Derived Tubular Aggregates. Journal of Neuroscience, 27, 9801-9815.  
&lt;br&gt;https://doi.org/10.1523/JNEUROSCI.2661-07.2007</mixed-citation></ref><ref id="hanspub.39796-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Plaisted, W.C., Zavala, A., Hingco, E., Tran, H., Coleman, R., Lane, T.E., Loring, J.F. and Walsh, C.M. (2016) Remyelination Is Correlated with Regulatory T Cell Induction Following Human Embryoid Body-Derived Neural Precursor Cell Transplantation in a Viral Model of Multiple Sclerosis. PLoS ONE, 11, e0157620.  
&lt;br&gt;https://doi.org/10.1371/journal.pone.0157620</mixed-citation></ref><ref id="hanspub.39796-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, C., et al. (2016) Treatment of Multiple Sclerosis by Transplantation of Neural Stem Cells Derived from Induced Pluripotent Stem Cells. Science China Life Sciences, 59, 950-957. &lt;br&gt;https://doi.org/10.1007/s11427-016-0114-9</mixed-citation></ref><ref id="hanspub.39796-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Nicaise, A.M., et al. (2017) iPS-Derived Neural Progenitor Cells from PPMS Patients Reveal Defect in Myelin Injury Response. Experimental Neurology, 288, 114-121. &lt;br&gt;https://doi.org/10.1016/j.expneurol.2016.11.012</mixed-citation></ref></ref-list></back></article>